XML 76 R62.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting - Reconciliation of Revenue to Net Profit (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue $ 86,679   $ 92,274   $ 171,364 $ 164,323
Less:            
Depreciation and amortization expense         7,322 7,364
Stock-based compensation expense 9,424   16,399   18,355 32,972
Litigation settlement expense 350   0   5,710 0
Interest income, net (2,364)   (2,826)   (5,148) (5,711)
Net loss (8,568) $ (10,353) (4,623) $ (19,888) (18,921) (24,511)
Testing services revenue            
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue 62,033   70,918   123,954 124,755
Less:            
Cost of test services, product, and patient and digital solutions 15,406   14,308   30,519 27,940
Product revenue            
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue 11,833   10,610   22,643 19,204
Less:            
Cost of test services, product, and patient and digital solutions 4,981   6,298   10,567 11,642
Patient and digital solutions revenue            
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue 12,813   10,746   24,767 20,364
Less:            
Cost of test services, product, and patient and digital solutions 8,271   7,393   15,987 14,351
Reportable Segment            
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue 86,679   92,274   171,364 164,323
Less:            
Personnel cost 29,330   30,843   60,073 57,371
Professional and legal fees 12,348   10,033   22,540 22,206
Research materials and clinical trials expense 4,057   4,724   7,231 8,204
Depreciation and amortization expense 2,951   3,108   5,901 6,486
Stock-based compensation expense 9,424   16,399   18,355 32,972
Litigation settlement expense 350   0   5,710 0
Transformational initiative costs 1,871   0   1,871 0
Other segment items 10,189   8,527   19,970 17,450
Interest income, net (2,364)   (2,826)   (5,147) (5,712)
Net loss (8,568)   (4,623)   (18,921) (24,511)
Reportable Segment | Testing services revenue            
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue 62,033   70,918   123,954 124,755
Less:            
Cost of test services, product, and patient and digital solutions 14,731   13,622   29,134 26,468
Reportable Segment | Product revenue            
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue 11,833   10,610   22,643 19,204
Less:            
Cost of test services, product, and patient and digital solutions 4,431   5,662   9,374 10,269
Reportable Segment | Patient and digital solutions revenue            
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]            
Total revenue 12,813   10,746   24,767 20,364
Less:            
Cost of test services, product, and patient and digital solutions $ 7,929   $ 6,805   $ 15,273 $ 13,120